Does UnitedHealthcare Cover Vardenafil (Levitra/Staxyn)?

What formulary tier is vardenafil on UnitedHealthcare plans?

On most UnitedHealthcare commercial PPO and HMO plans, vardenafil sits at Tier 3, the non-preferred brand level. Tier placement determines your copay or coinsurance directly. A Tier 3 drug typically costs members $60 to $120 per 30-day supply after deductible, depending on the specific plan design. Generic vardenafil, when listed separately, may fall to Tier 2 on some formularies, cutting that out-of-pocket figure significantly.

Formulary tiers shift every January 1 when UHC updates its drug list. Your 2025 plan documents, accessible through the UHC member portal at myuhc.com, show the exact tier and any quantity limits attached to vardenafil on your specific benefit. Quantity limits are common for PDE5 inhibitors; six tablets per 30 days is a frequently applied cap across UHC commercial products.

Vardenafil received FDA approval as a 5 mg, 10 mg, and 20 mg tablet on August 19, 2003, for the treatment of erectile dysfunction in adult men [1]. The orally disintegrating formulation (Staxyn 10 mg) received separate FDA approval on October 18, 2010 [1]. Because Staxyn carries a distinct NDC from Levitra, some UHC formularies tier the two products differently. Always verify both NDC numbers when checking coverage.

Erectile dysfunction affects an estimated 30 million men in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases [2]. The condition is independently associated with cardiovascular risk factors including hypertension, dyslipidemia, and type 2 diabetes [3]. UHC's clinical coverage policies for vardenafil reflect that context, typically requiring documentation of a diagnosed medical condition rather than treating the prescription as purely lifestyle-related.

Does UnitedHealthcare require prior authorization for vardenafil?

Prior authorization (PA) is required on virtually all UHC commercial plans that include vardenafil. The PA process sits at moderate difficulty, meaning approval rates are reasonable when documentation is complete, but incomplete submissions result in automatic denials that delay treatment. [4]

The prescribing physician submits a PA request through UHC's provider portal or by fax. UHC is required by most state laws and its own internal standards to return a decision within 72 hours for non-urgent requests and 24 hours for urgent clinical situations. [5]

Standard PA criteria UHC typically applies to vardenafil:

• A confirmed diagnosis of erectile dysfunction (ICD-10-CM code N52.x) documented in the medical record
• Age 18 or older
• Absence of contraindications, specifically concurrent use of nitrates in any form, since the combination causes potentially fatal hypotension [6]
• Documentation that the prescribing provider has reviewed cardiovascular risk given that sexual activity itself carries metabolic demand [7]
• On many plans, evidence that at least one preferred PDE5 inhibitor (sildenafil or tadalafil) was trialed and either failed or caused intolerable adverse effects

A 2003 Phase III trial by Porst et al. (N=805) demonstrated that vardenafil 10 mg and 20 mg produced statistically significant improvements on the International Index of Erectile Function (IIEF) erectile function domain score versus placebo (P<0.001), with 71% of intercourse attempts successful on 20 mg versus 30% on placebo [8]. Having this clinical evidence available helps a prescriber frame the medical necessity argument clearly in a PA letter.

The table below outlines the documentation your physician should gather before submitting the PA, based on the HealthRX PA Preparation Framework developed by our clinical pharmacists.

PA Preparation Framework for Vardenafil on UHC:

1. Printed or electronic medical record note with ICD-10-CM N52.x and onset history
2. Current medication list confirming no nitrate use (isosorbide mononitrate, nitroglycerin, amyl nitrite)
3. Cardiovascular risk assessment note or most recent cardiology clearance if applicable
4. Step therapy documentation: dates, doses, and outcomes of any prior sildenafil or tadalafil trials
5. Prescriber's clinical rationale for selecting vardenafil specifically (e.g., faster onset in patients with type 2 diabetes, tolerability profile)

Submitting all five components in the first PA request reduces the chance of an administrative denial and shortens time to approval.

What step therapy does UnitedHealthcare require before vardenafil?

Step therapy means the plan requires you to try and fail a preferred drug before it covers the requested drug. UHC commonly requires a documented trial of sildenafil (generic Viagra) or tadalafil (generic Cialis) before approving vardenafil. Both sildenafil and tadalafil are available as low-cost generics, making them the formulary-preferred options from a cost-management standpoint.

Sildenafil generic 100 mg tablets retail for under $20 per month at most major pharmacies [9]. Tadalafil 20 mg generic retails for a comparable amount. UHC formulary management logic is straightforward: if a cheaper therapeutic equivalent exists and the member has not tried it, the plan expects that trial first.

Step therapy exemptions that may apply:

• Prior use of sildenafil or tadalafil with documented adverse effects (severe flushing, visual disturbance, myalgia, or priapism)
• Drug interactions that preclude use of sildenafil or tadalafil (e.g., concurrent CYP3A4 inhibitors at doses that create greater safety concerns with sildenafil's longer half-life)
• Physician attestation that a clinical reason makes vardenafil the appropriate first-line choice for a specific patient

The American Urological Association's 2018 guidelines on erectile dysfunction state that all three oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are first-line treatments with comparable overall efficacy, though individual patient response varies [10]. That guideline language is useful when a prescriber argues against mandatory step therapy in a PA letter.

Many states have enacted step therapy reform laws requiring insurers to grant exemptions when step therapy is clinically inappropriate. The National Conference of State Legislatures tracks these statutes, and as of 2024, more than 30 states have some form of step therapy protection law in effect [11]. If your state has such a law, your prescriber can cite it directly in the PA request or appeal.

How do I appeal a UnitedHealthcare denial of vardenafil?

A denial is not final. UHC offers a two-level internal appeal process followed by an external independent review if the internal appeals fail. Knowing the timeline and the right arguments at each stage is the difference between continued denial and approved coverage.

Level 1 Internal Appeal:

File within 180 days of receiving the denial notice. Submit a written appeal to the address listed on the Explanation of Benefits (EOB) or denial letter. Include the prescribing physician's letter of medical necessity, the clinical documentation listed in the PA framework above, and a copy of the denial notice. UHC must respond within 30 days for standard appeals and 72 hours for expedited appeals involving urgent clinical need [12].

Level 2 Internal Appeal:

If Level 1 is denied, file a second internal appeal within 60 days of that denial. This review goes to a different UHC medical reviewer. Strengthen the submission with peer-reviewed literature, such as the Porst et al. Phase III data showing 71% successful intercourse attempts on vardenafil 20 mg [8], and any additional clinical notes your physician can provide.

External Independent Review Organization (IRO):

After exhausting internal appeals, you have the right to an external review by an IRO under the Affordable Care Act [13]. The IRO reviewer is completely independent of UHC. Submit the request within four months of the final internal denial. IRO decisions are binding on the insurer. Studies of external review programs show that members win a meaningful percentage of external reviews, particularly when the denial was based on medical necessity rather than a formulary exclusion [14].

The U.S. Department of Labor's Employee Benefits Security Administration (EBSA) at dol.gov/agencies/ebsa provides the formal external review process guidance for employer-sponsored plans [12]. For individual and marketplace plans, your state insurance commissioner oversees the external review process.

Practical appeal tips:

• Request the specific clinical criteria UHC used to deny the claim. They are required to provide these.
• Ask your physician to call the UHC peer-to-peer review line within 24 to 48 hours of a PA denial. A direct clinician-to-clinician conversation resolves many denials before a formal appeal is even filed.
• If the denial cites a formulary exclusion rather than medical necessity, the appeal strategy shifts. A formulary exclusion appeal argues medical necessity exception and requires stronger clinical differentiation.

What does vardenafil cost without UnitedHealthcare coverage?

If UHC denies coverage or your plan excludes ED medications entirely, you have several cost-reduction paths. Generic vardenafil is the most practical option. The FDA approved the first generic vardenafil in 2018 [15], and multiple manufacturers now produce it.

Generic vardenafil 20 mg (30 tablets) averages approximately $120 per month at GoodRx-negotiated cash prices at major chain pharmacies [9]. That compares to roughly $350 per month for brand-name Levitra. The pharmacological profile is identical: same active moiety, same 4-to-5-hour half-life, same mechanism of selective PDE5 inhibition [6].

Vardenafil inhibits phosphodiesterase type 5 (PDE5), which degrades cyclic GMP in smooth muscle cells of the corpus cavernosum. By blocking PDE5, vardenafil prolongs the vasodilatory effect of nitric oxide released during sexual stimulation, allowing sustained penile erection [6]. The 10 mg dose produces peak plasma concentration (Tmax) in approximately 0.7 to 0.9 hours in fasted men [1].

Cost options when UHC denies or excludes vardenafil:

• Generic vardenafil at cash price: approximately $120/month
• Manufacturer patient assistance programs: Bayer (Levitra's original manufacturer) offers assistance for qualifying low-income patients through its patient assistance program
• Telehealth pharmacy services: several platforms offer generic vardenafil at $1 to $2 per dose with a digital prescription
• 90-day supply at Costco or Sam's Club pharmacy: often lower per-unit cost than 30-day fills

How does vardenafil's clinical profile affect the coverage argument?

Understanding the pharmacology strengthens a medical necessity appeal. Vardenafil has a selectivity ratio for PDE5 over PDE6 (found in retinal rods) of roughly 15:1, compared to sildenafil's approximately 10:1 ratio [6]. That higher selectivity may reduce visual side effects, a clinically relevant distinction for patients who experienced blue-tinge visual disturbance or photophobia on sildenafil [16].

In patients with type 2 diabetes, a condition that independently impairs erectile function through autonomic neuropathy and endothelial dysfunction, vardenafil 10 mg and 20 mg showed statistically significant improvements versus placebo in a randomized controlled trial published in Diabetes Care [17]. The erectile function domain score improved by 6.6 points on 20 mg versus 1.9 points on placebo (P<0.001) [17]. Diabetes affects over 37 million Americans as of 2024, according to the CDC [18], and ED occurs in 35 to 75 percent of men with diabetes [19]. A prescriber treating a diabetic patient with ED has a strong clinical argument for vardenafil specifically.

Vardenafil also carries a shorter Tmax than tadalafil (0.7 to 0.9 hours versus 2 hours for tadalafil) [1][20], which some patients prefer for spontaneity. This pharmacokinetic distinction belongs in a PA letter when the prescriber is arguing why vardenafil is medically preferred over tadalafil for a specific patient.

The cardiovascular safety profile of vardenafil was examined in a pooled analysis of 5,994 patients across multiple Phase II and III trials, finding no increase in myocardial infarction rate compared to age-matched population norms [21]. The FDA label carries a precaution about QT prolongation with vardenafil, particularly in patients taking Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol) [1]. That interaction is a genuine contraindication that a reviewing physician should document has been assessed.

Does UHC cover vardenafil for conditions other than erectile dysfunction?

Vardenafil is FDA-approved only for erectile dysfunction in adult men. Off-label use is possible but coverage is far less likely. UHC's medical necessity criteria are written around the approved indication.

Pulmonary arterial hypertension (PAH) is sometimes treated off-label with PDE5 inhibitors, but sildenafil (Revatio, 20 mg) and tadalafil (Adcirca/Tadliq) carry FDA approval specifically for PAH [22][23]. UHC has separate formulary entries for those approved PAH indications and covers them under different PA criteria. Attempting to obtain vardenafil coverage for PAH through a UHC commercial plan is unlikely to succeed; the prescriber would be better served requesting sildenafil 20 mg (Revatio formulation) instead.

Vardenafil has no FDA-approved indication for weight loss, sexual dysfunction in women, or any other condition. Coverage for those uses would require an off-label medical necessity appeal with a very high evidentiary bar.

What are UHC's quantity limits for vardenafil?

Most UHC commercial plans cap vardenafil at six tablets per 30-day supply. Some plans allow eight tablets per 30 days. Quantity limit exceptions require a separate PA argument that clinical need exceeds the standard limit.

Requests for higher quantities generally require documentation of frequency of sexual activity, a treating urologist or men's health specialist supporting the request, and sometimes a behavioral or psychological evaluation ruling out compulsive behavior. The quantity limit is separate from the PA for the drug itself; a plan can approve the drug but deny the quantity exception.

Telehealth and HealthRX as an alternative path

When insurance coverage is denied or the PA process stalls, a telehealth platform with licensed prescribers can issue a prescription for generic vardenafil that you fill at cash price. HealthRX-affiliated physicians are licensed in 48 states and can evaluate and prescribe vardenafil where clinically appropriate. A completed intake, including a cardiovascular and medication review to confirm no nitrate use, takes approximately 15 minutes. Generic vardenafil at the doses studied in clinical trials (10 mg and 20 mg) is available through HealthRX partner pharmacies at competitive cash pricing without requiring insurer approval.